Skip to content
10-Q

Quarterly Report

CERO THERAPEUTICS HOLDINGS, INC. CERO CEROW

0001213900-26-057753

← back to feed
Filed
May 15, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 14, 2026 45.11M sh
Shares Diluted Q1 2026 · Mar 31, 2026 28.76M sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 171.38K sh
Dividends Paid Q1 2026 · Mar 31, 2026 $127.14K
Operating Cash Flow Q1 2026 · Mar 31, 2026 $2.8M
Long Term Debt Q1 2026 · Mar 31, 2026 $136.77K
Stockholders Equity Q1 2026 · Mar 31, 2026 −$9.26M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$5.45M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$329.39K
Stockholders Equity Q1 2026 · Dec 31, 2024 −$1.89M
Current Liabilities Q1 2026 · Mar 31, 2026 $11.33M
Current Liabilities Q1 2026 · Dec 31, 2025 $9.09M
Total Liabilities Q1 2026 · Mar 31, 2026 $11.46M
Total Liabilities Q1 2026 · Dec 31, 2025 $9.09M
Current Assets Q1 2026 · Mar 31, 2026 $1.57M
Current Assets Q1 2026 · Dec 31, 2025 $2.73M
Total Assets Q1 2026 · Mar 31, 2026 $2.21M
Total Assets Q1 2026 · Dec 31, 2025 $3.64M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.20
Eps Diluted restated Q1 2026 · Mar 31, 2025 −$31.82
Eps Basic Q1 2026 · Mar 31, 2026 −$0.20
Eps Basic restated Q1 2026 · Mar 31, 2025 −$31.82
Sga Expense Q1 2026 · Mar 31, 2026 $2.51M
Sga Expense Q1 2026 · Mar 31, 2025 $2.04M
Rd Expense Q1 2026 · Mar 31, 2026 $2.34M
Rd Expense Q1 2026 · Mar 31, 2025 $2.91M
Net Income Q1 2026 · Mar 31, 2026 −$5.89M
Net Income Q1 2026 · Mar 31, 2025 −$5.11M
Operating Income Q1 2026 · Mar 31, 2026 −$4.85M
Operating Income Q1 2026 · Mar 31, 2025 −$4.95M